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Ochroconis gallopava is an anamorphic mould characterized by slow growth rate and production of a
maroon pigment, which has been isolated worldwide from soil, thermal springs, decaying vegetation,
and chicken litter. It has been reported to cause localized, mostly pulmonary, and systemic infection in
severely immunocompromised patients.
We describe the case of a 76-year-old woman known for ulcerative colitis-related bronchiectasis
treated with low dose oral steroids, who developed a fungal bronchitis with dark, bloody-like, sputum
which was initially misinterpreted as haemoptysis. A ﬁlamentary mould grew on sputum culture, and
was identiﬁed by DNA analysis as Ochroconis gallopava. We observed a signiﬁcant clinical improvement
after 6 weeks of itraconazole therapy.
© 2017 Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).1. Case report
A 76-year-old woman, who never smoked, known for ulcerative
colitis-related bronchiectasis, reported an increasing quantity of
dark sputum and shortness of breath since 3 months. She reported
every morning the expectoration of a small cup of dark brownish-
red sputum. She denied fever, weight loss or other constitutional
symptoms. Further, she reported several self-limited episodes of
was describes as non-hypoxemic haemoptysis episodes over the
last year. On chest CT scan, the bronchiectasis was progressive over
the last 3 years and predominant in the lower lobes. Ulcerative
colitis was currently in remission under an oral treatment of
mesalazine and prednisolone <10mg/day. The past medical history
revealed corticosteroid-induced osteoporosis, peripheral artery
occlusive disease, and a previous alcohol abuse. Physical exami-
nation showed a slightly malnourished woman in preserved gen-
eral condition, and normal vital parameters. Lung auscultation
revealed humid rales over both lung bases. Clubbing was absent.
The current treatment includedprednisolone 7.5mg/day, inhaled
budenoside, mesalazine, calcium and vitamin D, azithromycin 250
mg 3 times a week, clopidogrel and levetiracetam.icine, Ospedale Regionale di
ernasconi).
n open access article under the CCLab results showed increased inﬂammatory parameters (CRP 38
mg/L, leucocytes 12.5 G/L with a slight lymphopenia of 1.3 G/L).
Pulmonary functions tests showed normal static and dynamic lung
volumes andamild reductionof carbonmonoxide diffusion capacity.
Chest X-ray and chest CT-scan showed large cylindrical bronchiec-
tasis with right lower lobe predominance, diffuse bronchial wall
thickening, and mucus plugging (Fig. 1). Sputum cytology showed
many leucocytes but no erythrocytes or haemosiderophages.
The initial differential diagnosis included a lower respiratory
tract bacterial infection, haemoptysis in the context of bronchiec-
tasis and tortuous bronchial arteries, or allergic bronchopulmonary
aspergillosis. The latter diagnosis was ruled out by the absence of
asthma, normal total IgE levels (47 kU/L), and negative sputum
cultures for Aspergillus. Other diagnoses such as pulmonary em-
bolism or vasculitis were considered unlikely considering the
clinical presentation.
An empirical treatment with moxiﬂoxacine was administered
for 14 days without any improvement. Sputum culture showed no
growth of bacteria or yeast. However, mould culture grew 34 col-
onies of a ﬁlamentary mould producing a red pigment, which was
identiﬁed as Ochroconis gallopava (also called Ochroconis gallopa-
vum) by DNA analysis (Fig. 2). Fungigram showed a minimum
inhibitory concentration (MIC) of 0.12 ml/L, 0.06 ml/L and 0.03 ml/L
for itraconazole, voriconazole and posaconazole, respectively.
The slow clinical deterioration with increasing bronchorrhea,BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Chest X-ray and CT scan showing bronchiectasis with air-ﬂuid levels, and bronchial wall thickening with right lower lobe predominance.
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other relevant pathogens, and the lack of clinical improvement
with antibiotic treatment led to the diagnosis of a fungal bronchitis.
Itraconazole 200mg/day was administered orally for 6 weeks with
a clinical improvement and disappearance of brownish-red
sputum. One month after treatment completion, the sputum cul-
ture for mould was sterile.2. Discussion
This case illustrates the occurrence of acute bronchitis due to
O. gallopava in an immunocompetent patient with bronchiectasis.
So far, only one case of a pulmonary infection caused by this fungus
in an elderly immunocompetent host with bronchiectasis was re-
ported [1].
O. gallopava is a melanin producing [2] anamorphic mould
characterized by slow growth rate and production of a red to
maroon pigment which was initially observed to cause epidemic
avian encephalitis, and which was recently transferred to the new
genus Verruconis [3]. It has been isolated worldwide from soil,
thermal springs, decaying vegetation, and chicken litter. It is the
most pathogenic species from the genus Ochroconis in humans and
may causes localized, mostly pulmonary, and systemic infection inFig. 2. A and B: Culture of Ochroconis gallopava. A, macroscopic aspect of colony on Sabour
the colony. B, microscopic aspect of the same colony showing two-celled conidia (lactophe
legend, the reader is referred to the web version of this article.)immunocompromised hosts [4]. Solid organ transplant patients are
particularly at risk for infections by this pathogen and survival is
dramatically reduced if brain infection occurs [5]. Although bron-
chiectasis may predispose to colonisation and infection by fungi,
O. gallopava as the causal agent has been reported so far in only one
case [1]. There is no report of such infection in cystic ﬁbrosis.
However, as this organism is poorly known and difﬁcult to identify
by conventional cultures, colonisation and infection may be under-
recognized. DNA sequencing of the internal transcribed spacer no. 2
of the nuclear rRNA gene operon or of the D2 region of large-
subunit ribosomal RNA gene are the gold standard for identiﬁca-
tion and should therefore be early considered [6].
Our patient presented with brownish-red sputum which was
misinterpreted as haemoptysis for several months in the context of
bronchiectasis. Ochroconis produces a red to marron pigment
which may be mistaken for coagulated blood. This case illustrates
the interest of sputum analysis to conﬁrm presence of erythrocytes
or haemosiderophages before performing invasive diagnostic and
therapeutic intervention such as bronchoscopy, or bronchial artery
embolization.
We observed a signiﬁcant clinical improvement after a 6-week
treatmentwith itraconazole in anhost treatedwith lowdose steroid
and without clinical signs of central nervous system involvement.aud medium after four days of growth at 30 C showing red to maroon pigment around
nol cotton blue staining). (For interpretation of the references to colour in this ﬁgure
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regimens for Ochroconis species. However, several reports suggest
that posaconazole and itraconazole may be effective, followed by
amphothericin B and voriconazole [5,7e10]. These results are in
agreement with in vitro susceptibility data [11] as well as the MIC
values observed in our case. Early diagnosis and treatment of
O. gallopava infection is mandatory to avoid dissemination to the
brain, which carries a very poor prognosis [12]. The good penetra-
tion of posaconazole into the central nervous systemand its lowMIC
well below the serum levels achievable with standard dosing regi-
mens [13] supports its use for difﬁcult-to-treat disseminated brain
infections.
In summary, we report the occurrence of an O. gallopava acute
bronchitis in a patient with bronchiectasis with three relevant
features. Firstly, O. gallopava may cause symptomatic infection in a
patient with bronchiectasis taking only low dose of steroids. Sec-
ondly, infection with this mould secreting extracellular red to
maroon pigment may mimic haemoptysis. Thirdly, similarly to
immunocompromised patients, an azole-based antimycotic ther-
apy may be effective in this clinical context.
Established facts
Ochroconis gallopava may cause pulmonary and systemic
infection in severely immunocompromised patients.
Novel insights
Ochroconis gallopava bronchitis may cause dark, bloody-like,
sputum which may be misinterpreted as haemoptysis and occur
in non severe immunocompromised patients.
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